Sökning: id:"swepub:oai:gup.ub.gu.se/258666" >
Great advances in t...
Great advances in the systemic treatment in malignant melanoma patients : Stora framsteg för systemisk behandling vid malignt melanom.
-
Ullenhag, Gustav (författare)
-
Hansson, Johan (författare)
-
- Ny, Lars, 1967 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology
-
(creator_code:org_t)
- 2017
- 2017
- Svenska.
-
Ingår i: Lakartidningen. - 1652-7518. ; 114
- Relaterad länk:
-
https://gup.ub.gu.se...
Abstract
Ämnesord
Stäng
- Great advances in the systemic treatment in malignant melanoma patients Up until a few years ago there was no systemic treatment with the capacity to prolong overall survival for patients with advanced malignant melanoma. Several new treatments have been established in clinical practice in recent years and they belong to two main groups; checkpoint inhibitors and inhibitors of an intracellular pathway (MAP kinase). The latter drugs are only active in melanomas with an activating BRAF mutation, which is present in half of the patients. Side effect management is important and in particular for the checkpoint inhibitors, which activate the immune system and frequently provoke immune related reactions. The introduction of these new treatments has substantially improved prognosis and some patients might even be cured. Based on ongoing research, more therapeutic breakthroughs can be anticipated in the years to come.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- Antibodies
- Monoclonal
- adverse effects
- economics
- pharmacology
- therapeutic use
- Antineoplastic Agents
- adverse effects
- economics
- pharmacology
- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols
- CTLA-4 Antigen
- antagonists & inhibitors
- Humans
- Melanoma
- drug therapy
- economics
- immunology
- Mitogen-Activated Protein Kinase Kinases
- antagonists & inhibitors
- Oncolytic Virotherapy
- Programmed Cell Death 1 Receptor
- antagonists & inhibitors
- Protein Kinase Inhibitors
- adverse effects
- economics
- pharmacology
- therapeutic use
- Proto-Oncogene Proteins B-raf
- antagonists & inhibitors
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas